The Kenya Red Cross Society (KRCS) has announced a partnership with Novartis, a global healthcare company, to improve access to prevention, treatment, and care of Non Communicable Diseases (NCDs) in Kenya.
According to the WHO’s latest global status report on NCDs, NCDs causes an estimated 38 million deaths in 2012, with nearly three quarters of these deaths occurring in low and middle-income countries. In Kenya, NCDs account for close to 50 per cent of inpatient admissions and 40 per cent of hospital deaths, dominating healthcare budgets. By 2030, NCDs are expected to contribute to approximately 60 per cent of the total national mortality.
As part of the new partnership with Novartis, KRCS will train health workers, community volunteers and scale up screening at community and facility level for NCDs over the next three years. KRCS will also purchase the Novartis Access portfolio to improve access to NCD prevention, treatment, care and support. KRCS will also focus on thousands of refugees living in the Kakuma and Dadaab refugee camps, as they are facing significant cases of diabetes, hypertension, cancer and asthma.
The support will ensure affordable medicine to the Level Five hospital in the IFO2 camp managed by KRCS. Currently, KRCS supports and follows up 151 patients living with NCDs. In line with the national NCD strategic plan launched by the Kenyan government in 2015 to prevent and control NCDs, the KRCS is stepping up efforts to fight NCDs. With support from its partners, KRCS is also implementing an NCD prevention and management programme in Nyeri and Nairobi counties focusing on awareness creation on risk factors, screening for early detection and linkage to treatment, care and support.